EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice

Begoña Porteiro, Reinout L P Roscam Abbing, Wietse In Het Panhuis, Dirk R de Waart, Suzanne Duijst, Isabelle Bolt, Esther W Vogels, Johannes H M Levels, Laura A Bosmans, Winnie G Vos, Ronald P J Oude Elferink, Esther Lutgens und 1 weitere

Journal of Lipid Research · 2024

DOI: 10.1016/j.jlr.2024.100594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Begoña Porteiro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Amsterd…. Hauptthemen laut MEDLINE: Atherosclerosis, Bile Acids and Salts, Liver, Receptors, LDL. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bile salts can strongly influence energy metabolism through systemic signaling, which can be enhanced by inhibiting the hepatic bile salt transporter Na+ taurocholate cotransporting polypeptide (NTCP), thereby delaying hepatic reuptake of bile salts to increase systemic bile salt levels. Bulevirtide is an NTCP inhibitor and was originally developed to prevent NTCP-mediated entry of Hepatitis B and D into hepatocytes. We previously demonstrated that NTCP inhibition lowers body weight, induces glucagon-like peptide-1 (GLP1) secretion, and lowers plasma cholesterol levels in murine obesity models. In humans, a genetic loss-of-function variant of NTCP has been associated with reduced plasma cholesterol levels. Here, we aimed to assess if Bulevirtide treatment attenuates atherosclerosis development by treating female Ldlr-/- mice with Bulevirtide or vehicle for 11 weeks. Since this did not result in the expected increase in plasma bile salt levels, we generated Oatp1a1-/-Ldlr-/- mice, an atherosclerosis-prone model with human-like hepatic bile salt uptake characteristics. These mice showed delayed plasma clearance of bile salts and elevated bile salt levels upon Bulevirtide treatment. At the study endpoint, Bulevirtide-treated female Oatp1a1-/-Ldlr-/- mice had reduced atherosclerotic lesion area in the aortic root that coincided with lowered plasma LDL-c levels, independent of intestinal cholesterol absorption. In conclusion, Bulevirtide, which is considered safe and is EMA-approved for the treatment of Hepatitis D, reduces atherosclerotic lesion area by reducing plasma LDL-c levels. We anticipate that its application may extend to atherosclerotic cardiovascular diseases, which warrants clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisBile Acids and SaltsLiverReceptors, LDLAnimalsFemaleMiceMice, KnockoutOrganic Anion TransportersOrganic Anion Transporters, Sodium-DependentSymportersOrganic Cation Transport Proteins

Stichwörter der Autor:innen

LDLbile acids and salts/metabolismcholesteroldyslipidemiasliver

Substanzen

Bile Acids and SaltsOrganic Anion TransportersOrganic Anion Transporters, Sodium-DependentReceptors, LDLSymportersOrganic Cation Transport Proteinssodium-bile acid cotransporterSLCO1A1 protein, mouseLdlr protein, mouse

Autor:innen und Institutionen

  • Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam Un…
  • Amsterdam UMC, Department of Experimental Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam UMC, location AMC, Department of Medical Biochemistry, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, The Netherlands;…

Förderung

  • European Research Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Porteiro, B., Roscam Abbing, R. L. P., In Het Panhuis, W., de Waart, D. R., Duijst, S., Bolt, I., Vogels, E. W., Levels, J. H. M., Bosmans, L. A., Vos, W. G., Oude Elferink, R. P. J., Lutgens, E., & van de Graaf, S. F. J. (2024). Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100594

Vancouver

Porteiro B, Roscam Abbing RLP, In Het Panhuis W, de Waart DR, Duijst S, Bolt I, et al. Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100594

BibTeX
@article{Porteiro2024,
  author = {Porteiro, Begoña and Roscam Abbing, Reinout L P and In Het Panhuis, Wietse and de Waart, Dirk R and Duijst, Suzanne and Bolt, Isabelle and Vogels, Esther W and Levels, Johannes H M and Bosmans, Laura A and Vos, Winnie G and Oude Elferink, Ronald P J and Lutgens, Esther and van de Graaf, Stan F J},
  title = {Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2024.100594}
}
Kostenlos starten →